Metastatic castration resistant prostate cancer (mCRPCa) is an invariably fatal malignancy. It has a strong predisposition to forming bone metastases, with upwards of 90% of patients suffering these during their illness, often with bone being the only site of metastasis.
A survival advantage was shown in the phase III trial ALSYMPCA where patients were treated with a bone-targeting a-emitting agent, namely radium-223 (223Ra). 223Ra is a calcium mimetic and it’s uptake into high-turnover areas of bone is not dependent on a particular malignant signalling process.
It is therefore hypothesised that 223Ra could be of benefit in a range of malignancies with a predisposition to forming bony metastases such as breast, lung, kidney and myeloma and includes those with a favourable long-term survival probability. Accordingly there is a growing need for fundamental questions relating to the radiobiological risks of such internalised exposures to be addressed.
This study uses a range of endpoints to understand the biological action of 223Ra in vivo in humans and to address the question of long-term bone marrow (BM) complications, including therapy-related leukaemogenesis, of this treatment.
Meet the Principal Investigator(s) for the project
Related Research Group(s)
Partnering with confidence
Organisations interested in our research can partner with us with confidence backed by an external and independent benchmark: The Knowledge Exchange Framework. Read more.
Project last modified 16/01/2024